ClinicalTrials.Veeva

Menu
P

Panax Clinical Research | Miami Lakes, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SEL-212
BI 685509
ALT-801
Plozasiran
Relamorelin
Nitazoxanide
HU6
Amisulpride
Tirzepatide
RDX013

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 53 total trials

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in hea...

Enrolling
Hepatic Impairment
Healthy Volunteers
Drug: Repotrectinib
Locations recently updated

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with mod...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: KarXT

This study is open to adults who are at least 18 years old and have* presumed or confirmed NASH together with overweight or obesity and* a body mass...

Enrolling
Non-Alcoholic SteatoHepatitis (NASH)
Obesity
Drug: Survodutide
Drug: Placebo

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics...

Enrolling
Hyperuricemia
Gout
Drug: dontinurad
Drug: dotinurad + allopurinol

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Active, not recruiting
Fatty Liver
Nonalcoholic Steatohepatitis
Drug: HU6
Other: Placebo

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). A...

Enrolling
Hypertriglyceridemia
Drug: Placebo
Drug: Plozasiran Injection

A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokine...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: BMF-219

The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with st...

Active, not recruiting
Rotator Cuff Tendinopathy
Drug: Secukinumab
Drug: Placebo

This is a double-blinded, two-arm, phase II study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoar...

Active, not recruiting
Symptomatic Knee Osteoarthritis
Drug: Placebo
Drug: DFV890

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (...

Enrolling
Severe Hypertriglyceridemia
Drug: Plozasiran Injection
Drug: Placebo
Locations recently updated

The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (H...

Enrolling
Hepatic Impairment
Healthy Participants
Drug: BMS-986278

Trial sponsors

Allergan logo
Boehringer Ingelheim logo
Lilly logo
Novartis logo
Pfizer logo
A
A
Arrowhead Pharmaceuticals logo
A
BioNTech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems